Shares of Concert Pharmaceuticals Inc (NASDAQ:CNCE) have received an average recommendation of “Buy” from the eleven analysts that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and seven have issued a buy recommendation on the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $21.29.

Several analysts have issued reports on the stock. BidaskClub raised shares of Westport Fuel Systems from a “hold” rating to a “buy” rating in a research report on Friday, July 12th. HC Wainwright set a $10.00 price target on shares of Novavax and gave the stock a “buy” rating in a research report on Thursday, June 13th. JMP Securities set a $79.00 price target on shares of LGI Homes and gave the stock a “buy” rating in a research report on Tuesday, April 9th. Mizuho reaffirmed a “buy” rating on shares of Supernus Pharmaceuticals in a research report on Friday, May 17th. Finally, Janney Montgomery Scott raised shares of Concert Pharmaceuticals from a “neutral” rating to a “buy” rating and upped their price target for the stock from $14.00 to $16.00 in a research report on Thursday, June 13th.

In other Concert Pharmaceuticals news, major shareholder Bvf Partners L. P/Il sold 386,289 shares of the company’s stock in a transaction on Monday, June 10th. The shares were sold at an average price of $10.70, for a total transaction of $4,133,292.30. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 9.40% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of CNCE. DekaBank Deutsche Girozentrale increased its holdings in shares of Concert Pharmaceuticals by 21.6% in the first quarter. DekaBank Deutsche Girozentrale now owns 9,000 shares of the biotechnology company’s stock valued at $143,000 after purchasing an additional 1,600 shares during the last quarter. Prudential Financial Inc. increased its holdings in shares of Concert Pharmaceuticals by 2.0% in the fourth quarter. Prudential Financial Inc. now owns 81,616 shares of the biotechnology company’s stock valued at $1,024,000 after purchasing an additional 1,610 shares during the last quarter. Steward Partners Investment Advisory LLC increased its holdings in shares of Concert Pharmaceuticals by 4.0% in the first quarter. Steward Partners Investment Advisory LLC now owns 61,035 shares of the biotechnology company’s stock valued at $736,000 after purchasing an additional 2,350 shares during the last quarter. Knott David M increased its holdings in shares of Concert Pharmaceuticals by 4.1% in the first quarter. Knott David M now owns 83,607 shares of the biotechnology company’s stock valued at $1,009,000 after purchasing an additional 3,307 shares during the last quarter. Finally, Great West Life Assurance Co. Can acquired a new position in shares of Concert Pharmaceuticals in the fourth quarter valued at $48,000. 74.60% of the stock is currently owned by hedge funds and other institutional investors.

Shares of CNCE stock traded down $0.18 during trading on Friday, reaching $10.75. The company’s stock had a trading volume of 73,400 shares, compared to its average volume of 169,091. The firm’s fifty day moving average is $11.25. The company has a current ratio of 20.44, a quick ratio of 20.44 and a debt-to-equity ratio of 0.11. The stock has a market capitalization of $255.85 million, a P/E ratio of -4.48 and a beta of 0.92. Concert Pharmaceuticals has a one year low of $9.21 and a one year high of $17.86.

Concert Pharmaceuticals (NASDAQ:CNCE) last announced its quarterly earnings data on Thursday, May 2nd. The biotechnology company reported ($0.93) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.62) by ($0.31). The business had revenue of $1.01 million during the quarter, compared to the consensus estimate of $16.08 million. Concert Pharmaceuticals had a negative return on equity of 41.72% and a negative net margin of 7,118.04%. On average, equities analysts forecast that Concert Pharmaceuticals will post -3.78 EPS for the current fiscal year.

Concert Pharmaceuticals Company Profile

Concert Pharmaceuticals, Inc operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for use in the treatment autoimmune and inflammatory diseases, and central nervous systems disorders. Its product candidates include AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease; CTP-730, a deuterated analog of apremilast that has completed the Phase 1 clinical trials for the treatment of inflammation or cancer; JZP-386, a once-nightly oxybate product; and CTP-543, which is in Phase 1 clinical trials for use in the treatment of alopecia areata.

Featured Article: How is a buy-side analyst different from a sell-side analyst?

Analyst Recommendations for Concert Pharmaceuticals (NASDAQ:CNCE)

Receive News & Ratings for Concert Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.